Quiet wakefulness: the influence of intraperitoneal and intranasal oxytocin on sleep-wake behavior and neurophysiology in rats.

"Disclosure Statement Financial disclosure statement: MTB is an inventor on patents and patent applications covering oxytocin-based therapeutics. He is co-founder and Chief Scientific Officer of Kinoxis Therapeutics Pty Ltd, a company commercializing some of this intellectual property. The other author(s) declared no financial arrangements or connections with respect to the research, authorship, and/or publication of this article. Non-financial disclosure ­statement: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article."

"Funding The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: funding from The University of Sydney and the National Health and Medical Research Council (NHMRC; APP1166044, APP1092046)."